$PALI
PALISADE BIO, INC.

2018 Q1 Form 10-Q Financial Statement

#000117184318003929 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $2.500K $2.500K
YoY Change 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.330M
YoY Change -11.28% -58.04%
% of Gross Profit
Research & Development $1.169M $2.902M
YoY Change -59.7% -5.33%
% of Gross Profit
Depreciation & Amortization $70.00K $110.0K
YoY Change -36.36% 22.22%
% of Gross Profit
Operating Expenses $2.351M $4.235M
YoY Change -44.47% -32.1%
Operating Profit -$2.349M -$4.232M
YoY Change -44.49% -32.11%
Interest Expense $1.920K $138.7K
YoY Change -98.62% -64.11%
% of Operating Profit
Other Income/Expense, Net $202.0K -$3.335M
YoY Change -106.06% 796.16%
Pretax Income -$2.150M -$7.570M
YoY Change -71.6% 14.52%
Income Tax
% Of Pretax Income
Net Earnings -$2.147M -$7.567M
YoY Change -71.63% 14.55%
Net Earnings / Revenue -85878.72% -302690.16%
Basic Earnings Per Share
Diluted Earnings Per Share -$16.54M -$84.11M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.720M $16.68M
YoY Change -41.73% 118.9%
Cash & Equivalents $9.724M $11.68M
Short-Term Investments $0.00 $5.000M
Other Short-Term Assets $350.0K $480.0K
YoY Change -27.08% -55.56%
Inventory
Prepaid Expenses $347.0K $477.1K
Receivables $137.4K $14.72K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.21M $17.17M
YoY Change -40.55% 96.53%
LONG-TERM ASSETS
Property, Plant & Equipment $149.7K $242.8K
YoY Change -38.36% -27.94%
Goodwill
YoY Change
Intangibles $839.3K $904.7K
YoY Change -7.23% -15.17%
Long-Term Investments
YoY Change
Other Assets $18.05K $15.82K
YoY Change 14.05% -72.57%
Total Long-Term Assets $1.341M $1.556M
YoY Change -13.81% 6.5%
TOTAL ASSETS
Total Short-Term Assets $10.21M $17.17M
Total Long-Term Assets $1.341M $1.556M
Total Assets $11.55M $18.73M
YoY Change -38.33% 83.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.170M $2.170M
YoY Change -46.08% -17.49%
Accrued Expenses $0.00 $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.531M
YoY Change -43.33%
Total Short-Term Liabilities $1.279M $5.048M
YoY Change -74.66% -33.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.660M $3.900M
YoY Change -6.15% 1850.0%
Total Long-Term Liabilities $3.660M $3.900M
YoY Change -6.15% 53.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.279M $5.048M
Total Long-Term Liabilities $3.660M $3.900M
Total Liabilities $4.943M $8.949M
YoY Change -44.76% -13.69%
SHAREHOLDERS EQUITY
Retained Earnings -$210.8M -$200.6M
YoY Change 5.11% 12.34%
Common Stock $151.6K $117.4K
YoY Change 29.1% -87.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.607M $9.780M
YoY Change
Total Liabilities & Shareholders Equity $11.55M $18.73M
YoY Change -38.33% 83.63%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.147M -$7.567M
YoY Change -71.63% 14.55%
Depreciation, Depletion And Amortization $70.00K $110.0K
YoY Change -36.36% 22.22%
Cash From Operating Activities -$1.847M -$4.436M
YoY Change -58.36% 27.1%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.000M $0.00
YoY Change -100.0%
Cash From Investing Activities $5.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00K
YoY Change
Debt Paid & Issued, Net $1.223M
YoY Change 11.45%
Cash From Financing Activities -104.2K 921.7K
YoY Change -111.31% -183.79%
NET CHANGE
Cash From Operating Activities -1.847M -4.436M
Cash From Investing Activities 5.000M
Cash From Financing Activities -104.2K 921.7K
Net Change In Cash 3.049M -3.514M
YoY Change -186.76% -221.18%
FREE CASH FLOW
Cash From Operating Activities -$1.847M -$4.436M
Capital Expenditures
Free Cash Flow -$4.436M
YoY Change 26.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
1169736
CY2017Q4 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
875065
CY2018Q1 cur Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
84000
CY2017Q1 cur Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
0
CY2018Q1 cur Expenses Related To The Inducement Of Warrants
ExpensesRelatedToTheInducementOfWarrants
CY2017Q1 cur Expenses Related To The Inducement Of Warrants
ExpensesRelatedToTheInducementOfWarrants
476084
CY2018Q1 cur Fees Related To Issuance Of Derivative Instrument And Other Expenses
FeesRelatedToIssuanceOfDerivativeInstrumentAndOtherExpenses
4021
CY2017Q1 cur Fees Related To Issuance Of Derivative Instrument And Other Expenses
FeesRelatedToIssuanceOfDerivativeInstrumentAndOtherExpenses
476084
CY2018Q1 cur Payments Of Fees Related To Prior Financing
PaymentsOfFeesRelatedToPriorFinancing
CY2017Q1 cur Payments Of Fees Related To Prior Financing
PaymentsOfFeesRelatedToPriorFinancing
11596
CY2018Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
418625
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2746
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2631
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217289009
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217050174
CY2018Q1 cur Proceeds From Exercise Of Stock Purchase Warrants Net Of Issuance Costs
ProceedsFromExerciseOfStockPurchaseWarrantsNetOfIssuanceCosts
CY2017Q1 cur Proceeds From Exercise Of Stock Purchase Warrants Net Of Issuance Costs
ProceedsFromExerciseOfStockPurchaseWarrantsNetOfIssuanceCosts
2200004
CY2018Q1 cur Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
CY2017Q1 cur Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
50000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
137372
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
312802
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238835
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
522439
CY2018Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
47654
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9500000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8300000
CY2018Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q1 us-gaap Assets
Assets
11549948
CY2017Q4 us-gaap Assets
Assets
13884456
CY2018Q1 us-gaap Assets Current
AssetsCurrent
10208615
CY2017Q4 us-gaap Assets Current
AssetsCurrent
12448799
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9724248
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6674940
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15194949
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11680499
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3049308
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3514450
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
67374
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
112205
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
190219
CY2017Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2741314
CY2018Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3662663
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3852882
CY2018Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
58784
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15160014
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15160014
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15160014
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15160014
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
151600
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
151600
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2146853
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7567425
CY2018Q1 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
334303
CY2017Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
365456
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
501
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-184
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
598000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1182054
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1332421
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
293119
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-227650
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-175430
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4224
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-418625
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-852963
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3335247
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2351495
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
4234507
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
220879
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2348995
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4232007
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18048
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13853
CY2018Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-89937
CY2017Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-84481
CY2018Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-7369
CY2017Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12542
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4000
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
159
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-704
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2080
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-56241
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-221649
CY2018Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
839314
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
883462
CY2018Q1 us-gaap Interest Expense
InterestExpense
1920
CY2017Q1 us-gaap Interest Expense
InterestExpense
138732
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
1920
CY2017Q1 us-gaap Interest Paid Net
InterestPaidNet
136718
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
17749
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20883
CY2018Q1 us-gaap Liabilities
Liabilities
4942837
CY2017Q4 us-gaap Liabilities
Liabilities
5369327
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11549948
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13884456
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1279002
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1514569
CY2018Q1 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
1172
CY2017Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
1876
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-104244
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
921696
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1846949
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4435962
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2146968
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-7567254
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
202027
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
115
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-171
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
109266
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
346995
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
402273
CY2018Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
5000000
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149668
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
172886
CY2018Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2017Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1222519
CY2018Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
104244
CY2017Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
94193
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1169441
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2902086
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210846244
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208699276
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2500
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2500
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
238835
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
522439
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6300000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1305205
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
5000000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
6607111
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
8515129
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.37
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
325444
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
94000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
108000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1894077
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1568633
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.76
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
46.32
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2018Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1568633
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15300
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y219D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y109D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y255D
CY2018Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
14.25
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><div style="display: inline; background-color: white">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div></div></div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15116937
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11140898

Files In Submission

Name View Source Status
0001171843-18-003929-index-headers.html Edgar Link pending
0001171843-18-003929-index.html Edgar Link pending
0001171843-18-003929.txt Edgar Link pending
0001171843-18-003929-xbrl.zip Edgar Link pending
clinicalpipeline.jpg Edgar Link pending
cur-20180331.xml Edgar Link completed
cur-20180331.xsd Edgar Link pending
cur-20180331_cal.xml Edgar Link unprocessable
cur-20180331_def.xml Edgar Link unprocessable
cur-20180331_lab.xml Edgar Link unprocessable
cur-20180331_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_051518p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending